| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | ZENO MANAGEMENT, INC. | 10275 SCIENCE CENTER DR STE 200 | SAN DIEGO | CA | 92121-1117 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 000 | 4 | NIH | 11/4/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $4,076 ) |
| | 2021 | 2018 | ZENO MANAGEMENT, INC. | 10275 SCIENCE CENTER DR STE 200 | SAN DIEGO | CA | 92121-1117 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 001 | 3 | NIH | 7/12/2021 | $4,076 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | ZENO MANAGEMENT, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 000 | 4 | NIH | 3/25/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,917,377 ) |
| | 2019 | 2019 | ZENO MANAGEMENT, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 003 | 4 | NIH | 5/31/2019 | $856,578 |
| | 2019 | 2018 | ZENO MANAGEMENT, INC | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 001 | 3 | NIH | 11/14/2018 | $1,060,799 |
|
|
